About QuidelOrtho Corporation - Common Stock (QDEL)
QuidelOrtho Corp is a prominent player in the field of medical diagnostics, specializing in the development and manufacture of diagnostic testing solutions. The company focuses on producing innovative products that aid in the rapid detection of infectious diseases and other critical health conditions, utilizing advanced technologies such as molecular diagnostics and immunoassay platforms. QuidelOrtho's portfolio includes a range of tests designed for use in various healthcare settings, including hospitals, laboratories, and physician offices, facilitating timely and accurate diagnoses that enhance patient care. Through its commitment to innovation and quality, the company strives to improve the health outcomes of individuals around the globe. Read More
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL)
jumped 41.1% in the afternoon session after the company reported decent first quarter 2025 results which significantly beat EPS and EBITDA expectations, though misses on full-year EPS guidance and constant currency revenue. Sales fell 3%, hurt by a sharp drop in COVID-19 and Donor Screening tests, even though core labs and respiratory (excluding COVID) grew at a solid pace. Zooming out, we think this was a decent quarter featuring some areas of strength but also some blemishes.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 2.6% year on year to $692.8 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.71 billion at the midpoint. Its non-GAAP profit of $0.74 per share was 25% above analysts’ consensus estimates.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - imaging, diagnostics stocks fared in Q4, starting with Hologic (NASDAQ:HOLX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including QuidelOrtho (NASDAQ:QDEL) and its peers.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at GE HealthCare (NASDAQ:GEHC) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including Lantheus (NASDAQ:LNTH) and its peers.
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio.
Over the last six months, QuidelOrtho’s shares have sunk to $40.10, producing a disappointing 7.7% loss - a stark contrast to the S&P 500’s 7.1% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.
QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025.
